RecruitingNCT07527715

Cardiac Magnetic Resonance-Clinical Prediction Model-Dilated Cardiomyopathy

Study on Risk Early Warning of Clinical Prediction Model Based on Multi-Parameter Stress Perfusion Cardiac Magnetic Resonance in Adverse Prognosis of Dilated Cardiomyopathy


Sponsor

Shandong Provincial Hospital

Enrollment

2,000 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

Dilated cardiomyopathy (DCM) is a common and serious heart disease characterized by left ventricular enlargement and impaired pumping function, with adverse prognosis (including heart failure, arrhythmia, heart-related hospitalization, and death) being a major concern for patients. Currently, a critical gap exists in accurately predicting which DCM patients are at high risk of these severe outcomes, limiting targeted clinical care. This observational, non-invasive study aims to develop and validate a clinical prediction model for early risk warning of adverse prognosis in DCM patients. The model integrates multi-parameter stress perfusion cardiac magnetic resonance (MP stress perfusion CMR)-a safe, high-resolution imaging technique that assesses cardiac structure, function, blood perfusion, and tissue damage under mild stress-and standard clinical data (e.g., age, gender, blood pressure, and routine heart test results). The model will be trained and tested using follow-up data from hundreds of DCM patients, with the analysis identifying patterns in CMR and clinical data associated with adverse outcomes. Once validated for accuracy, the model will provide doctors with personalized risk scores to prioritize care for high-risk patients (e.g., early intervention, close monitoring) and avoid over-treatment for lower-risk individuals. Beyond clinical application, the study will enhance understanding of DCM progression, laying the groundwork for improved diagnostic tools, more effective treatments, and better strategies to prevent DCM-related complications, ultimately improving patient quality of life and reducing mortality.


Eligibility

Min Age: 18 Years

Exclusion Criteria5

  • significant coronary artery disease (CAD), defined as a stenosis of ˃50% in a major coronary artery
  • infiltrative disease
  • valvular cardiomyopathy
  • arrhythmogenic cardiomyopathy
  • congenital heart disease

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERleft ventricular ejection fraction

HFrEF:LVEF\<40% ; HFmrEF:LVEF40-50%; HFpEF: LVEF\>50%


Locations(1)

Jinan central hospital

Jinan, Shandong, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07527715


Related Trials